Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H28O4 |
Molecular Weight | 344.4446 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC=C3[C@@]2([H])CCC4=CC(=O)CC[C@]34C
InChI
InChIKey=BCFCRXOJOFDUMZ-ONKRVSLGSA-N
InChI=1S/C21H28O4/c1-19-8-5-14(23)11-13(19)3-4-15-16(19)6-9-20(2)17(15)7-10-21(20,25)18(24)12-22/h6,11,15,17,22,25H,3-5,7-10,12H2,1-2H3/t15-,17+,19+,20+,21+/m1/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/17240253Curator's Comment: description was created based on several sources, including
http://www.businesswire.com/news/home/20090702005343/en/Alcon-Discontinues-Development-Anecortave-Acetate-Intraocular-Pressure
http://www.sec.gov/Archives/edgar/data/1167379/000116737908000065/acl6k0708anaacetateex991.pdf
https://www.ncbi.nlm.nih.gov/pubmed/23301619
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17240253
Curator's Comment: description was created based on several sources, including
http://www.businesswire.com/news/home/20090702005343/en/Alcon-Discontinues-Development-Anecortave-Acetate-Intraocular-Pressure
http://www.sec.gov/Archives/edgar/data/1167379/000116737908000065/acl6k0708anaacetateex991.pdf
https://www.ncbi.nlm.nih.gov/pubmed/23301619
Anecortave is a novel angiogenesis inhibitor used in the treatment of the exudative (wet) form of age-related macular degeneration. It will be marketed by Alcon as anecortave acetate (AA) for depot suspension under the trade name Retaane. In 2007 they received their letter of approval for Retaane’s indication to treat wet age-related macular degeneration (AMD), but final approval would require the completion of an additional clinical study. As a result, the Anecortave Acetate Risk-Reduction Trial (AART) was continued to be supported by Alcon. This study looked at the efficacy of Retaane to reduce the progression of the dry from of AMD to the wet-form. In 2008, Alcon Inc. announced they were terminating the development of anecortave acetate for the prevention of developing sight-threatening choroidal neovascularization secondary to age-related macular degeneration. In 2009, Alcon Inc. announced they would terminate the development of the drug for the reducing intraocular pressure associated with glaucoma. Currently, anecortave acetate is not on the market or being made for therapeutic use by Alcon Inc.[7] This could be due to the lack of efficacy of clinical trials with anecortave acetate or because of newer more efficacious products that are currently on the market. Anecortave acetate functions as an antiangiogenic agent, inhibiting blood vessel growth by decreasing extracellular protease expression and inhibiting endothelial cell migration. Its angiostatic activity does not seem to be mediated through any of the commonly known pharmacological receptors. RETAANE blocks signals from multiple growth factors because it acts downstream and independent of the initiating angiogenic stimuli and inhibits angiogenesis subsequent to the angiogenic stimulation. Recently was discovered, that phosphodiesterase 6-delta (PDE6D) was a molecular binding partner of AA and this provided insight into the role of this drug candidate in treating glaucoma.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3860 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23301619 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Secondary | Retaane Approved UseUnknown Launch Date2004 |
|||
Secondary | Retaane Approved UseUnknown Launch Date2004 |
PubMed
Title | Date | PubMed |
---|---|---|
Anecortave (Alcon Laboratories). | 2005 Apr |
|
Drug pricing for a novel treatment for wet macular degeneration: using incremental cost-effectiveness ratios to ensure societal value. | 2005 Jun |
|
Anecortave acetate in the treatment of age-related macular degeneration. | 2006 |
|
A preliminary benefit-risk assessment of verteporfin in age-related macular degeneration. | 2006 |
|
Triamcinolone acetonide and anecortave acetate do not stimulate uveal melanoma cell growth. | 2008 Sep 24 |
|
Anecortave acetate for fibrotic lesions with presence of residual peripheral activity in age-related macular degeneration. | 2008 Spring |
|
Anterior juxtascleral delivery of anecortave acetate in eyes with primary open-angle glaucoma: a pilot investigation. | 2009 Jan |
|
Suppression and reduction of corticosteroid-induced ocular hypertension by anecortave in sheep. | 2010 Mar |
Patents
Sample Use Guides
injection of three doses of anecortave acetate (24 mg, 48 mg and 60 mg)
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10440274
A murine uveal melanoma cell line (99E1) was transplanted intracamerally into athymic nude BALB/c mice. Mice were treated topically three times per day beginning on the day of tumor transplantation and continuing through day 28. Groups included (a) 1% anecortave acetate. Intraocular tumor weights were determined on days 10, 14, 21, and 28. The effect of the test agents on tumor cell proliferation was examined in vitro by [3H]thymidine incorporation.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QS01LA02
Created by
admin on Fri Dec 15 19:02:46 GMT 2023 , Edited by admin on Fri Dec 15 19:02:46 GMT 2023
|
||
|
WHO-ATC |
S01LA02
Created by
admin on Fri Dec 15 19:02:46 GMT 2023 , Edited by admin on Fri Dec 15 19:02:46 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
10184-70-0
Created by
admin on Fri Dec 15 19:02:46 GMT 2023 , Edited by admin on Fri Dec 15 19:02:46 GMT 2023
|
PRIMARY | |||
|
DB12081
Created by
admin on Fri Dec 15 19:02:46 GMT 2023 , Edited by admin on Fri Dec 15 19:02:46 GMT 2023
|
PRIMARY | |||
|
217
Created by
admin on Fri Dec 15 19:02:46 GMT 2023 , Edited by admin on Fri Dec 15 19:02:46 GMT 2023
|
PRIMARY | |||
|
100000180103
Created by
admin on Fri Dec 15 19:02:46 GMT 2023 , Edited by admin on Fri Dec 15 19:02:46 GMT 2023
|
PRIMARY | |||
|
DTXSID70144268
Created by
admin on Fri Dec 15 19:02:46 GMT 2023 , Edited by admin on Fri Dec 15 19:02:46 GMT 2023
|
PRIMARY | |||
|
R5Y8O51589
Created by
admin on Fri Dec 15 19:02:46 GMT 2023 , Edited by admin on Fri Dec 15 19:02:46 GMT 2023
|
PRIMARY | |||
|
7074810
Created by
admin on Fri Dec 15 19:02:46 GMT 2023 , Edited by admin on Fri Dec 15 19:02:46 GMT 2023
|
PRIMARY | |||
|
CHEMBL2106613
Created by
admin on Fri Dec 15 19:02:46 GMT 2023 , Edited by admin on Fri Dec 15 19:02:46 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PRODRUG (METABOLITE ACTIVE)